AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...
Healio4d
FDA approves Soliris for patients aged 6 years and up with generalized myasthenia gravis
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...
Navigating the Complexities of Interrelated Claim Disputes
The author writes "In the realm of insurance coverage litigation, whether two or more claims filed in different time periods ...